Natixis Advisors LLC cut its position in Organon & Co. (NYSE:OGN - Free Report) by 35.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,905 shares of the company's stock after selling 17,310 shares during the period. Natixis Advisors LLC's holdings in Organon & Co. were worth $461,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Barclays PLC raised its holdings in Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after acquiring an additional 84,136 shares during the last quarter. Weiss Asset Management LP acquired a new position in shares of Organon & Co. during the 3rd quarter valued at about $32,966,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Organon & Co. during the 4th quarter valued at about $2,263,000. Wedmont Private Capital grew its holdings in shares of Organon & Co. by 453.4% in the fourth quarter. Wedmont Private Capital now owns 100,539 shares of the company's stock valued at $1,594,000 after purchasing an additional 82,372 shares during the period. Finally, Sippican Capital Advisors increased its position in Organon & Co. by 138.7% during the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company's stock worth $542,000 after purchasing an additional 21,122 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.
Organon & Co. Stock Up 2.8 %
Shares of Organon & Co. stock traded up $0.41 during trading hours on Monday, reaching $14.92. 2,784,187 shares of the company were exchanged, compared to its average volume of 2,539,662. The firm has a market cap of $3.85 billion, a PE ratio of 4.48, a PEG ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock's fifty day moving average is $15.32 and its 200 day moving average is $16.17.
Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.51%. Organon & Co.'s payout ratio is 33.63%.
Analyst Upgrades and Downgrades
OGN has been the topic of several recent analyst reports. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Morgan Stanley decreased their price objective on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday, February 14th. Finally, Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $20.80.
Read Our Latest Analysis on OGN
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
